Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 02:03:41 UTC |
---|
Update Date | 2021-09-26 22:59:00 UTC |
---|
HMDB ID | HMDB0248630 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Arzoxifene |
---|
Description | Arzoxifene belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. Based on these results, Lilly announced they are discontinuing further development of the drug and would not seek regulatory approval. Arzoxifene is a very strong basic compound (based on its pKa). Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of arzoxifene will increase the risk of developing endometrial carcinoma. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. However arzoxifene failed to meet secondary endpoints of reduction in non-vertebral fractures and cardiovascular events and improvements in cognitive function. Arzoxifene (INN; developmental code name LY-353381) is a selective estrogen receptor modulator (SERM) of the benzothiophene group which was never marketed. It has antiestrogenic effects in the breast, mixed estrogenic and antiestrogenic effects in the uterus, and estrogenic effects in bone. A 2015 network meta-analysis found that arzoxifene significantly reduced the risk of breast cancer (RR 0.415) and to a greater extent than raloxifene (RR 0.572) or tamoxifen (RR 0.708). The medication has been found to suppress gonadotropin levels in postmenopausal women, increase sex hormone-binding globulin levels, and decrease insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 levels. This compound has been identified in human blood as reported by (PMID: 31557052 ). Arzoxifene is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Arzoxifene is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2 InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3 |
---|
Synonyms | Value | Source |
---|
LY353381hydrochloride | MeSH | 4'f-DMA | MeSH |
|
---|
Chemical Formula | C28H29NO4S |
---|
Average Molecular Weight | 475.6 |
---|
Monoisotopic Molecular Weight | 475.181729592 |
---|
IUPAC Name | 2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol |
---|
Traditional Name | arzoxifene |
---|
CAS Registry Number | Not Available |
---|
SMILES | COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2 |
---|
InChI Identifier | InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3 |
---|
InChI Key | MCGDSOGUHLTADD-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic oxygen compounds |
---|
Class | Organooxygen compounds |
---|
Sub Class | Ethers |
---|
Direct Parent | Diarylethers |
---|
Alternative Parents | |
---|
Substituents | - Diaryl ether
- 1-benzothiophene
- Benzothiophene
- Phenoxy compound
- Anisole
- Methoxybenzene
- Phenol ether
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Monocyclic benzene moiety
- Benzenoid
- Piperidine
- Heteroaromatic compound
- Thiophene
- Tertiary aliphatic amine
- Tertiary amine
- Organoheterocyclic compound
- Azacycle
- Organonitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic nitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Arzoxifene GC-MS (Non-derivatized) - 70eV, Positive | splash10-0002-9122200000-332110e8f38d72e671d9 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Arzoxifene GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Arzoxifene GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Arzoxifene GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 10V, Positive-QTOF | splash10-004i-0101900000-aa750811f649fa7de4a5 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 20V, Positive-QTOF | splash10-03fr-3921300000-ea6adb784497d7735e6a | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 40V, Positive-QTOF | splash10-00n0-9521200000-9f77974b55ab41b04661 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 10V, Negative-QTOF | splash10-00di-0002900000-1e45a349726fa04a1d69 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 20V, Negative-QTOF | splash10-0229-1019600000-b8677ff436af7942ac71 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 40V, Negative-QTOF | splash10-053r-2894000000-f1c88a0f313b895a2609 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 10V, Positive-QTOF | splash10-004i-0000900000-55ff159f78c22393e471 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 20V, Positive-QTOF | splash10-056r-0254900000-28a39a935dc51b384a57 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 40V, Positive-QTOF | splash10-03ea-9410100000-5c8368a25bbc295675e9 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 10V, Negative-QTOF | splash10-00di-0000900000-66c3f480b19eb52ac799 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 20V, Negative-QTOF | splash10-00di-0102900000-7322a22397bde01fe644 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Arzoxifene 40V, Negative-QTOF | splash10-052r-1298600000-0b7514489a43a80bc2bd | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|